Table 1 Summary of demographics and baseline characteristics
From: Treatment patterns and costs for anti-TNFα biologic therapy in patients with psoriatic arthritis
Patients With Only First-line Biologic Therapy (n = 881)a | Patients With Second-line Biologic Therapy (n = 72)b | Patients With Third-line or Greater Biologic Therapy (n = 37)a,b | Overall (N = 990) | |
|---|---|---|---|---|
Age (y), mean (SD) | 49.1 (11.0) | 48 (10.9) | 48.8 (9.5) | 49.0 (10.9) |
Female, n (%) | 387 (43.9) | 42 (58.3) | 22 (59.5) | 451 (45.6) |
US region, n (%) | ||||
Northeast | 127 (14.4) | 11 (15.3) | 4 (10.8) | 142 (14.3) |
North central | 209 (23.7) | 11 (15.3) | 8 (21.6) | 228 (23.0) |
South | 357 (40.5) | 32 (44.4) | 15 (40.5) | 404 (40.8) |
West | 182 (20.7) | 18 (25.0) | 10 (27.0) | 210 (21.2) |
Unknown | 6 (0.7) | 0 | 0 | 6.0 (0.6) |
Health insurance, n (%) | ||||
FFS | 721 (81.8) | 54 (75.0) | 32 (86.5) | 807 (81.5) |
HMO and POS capitation | 137 (15.6) | 18 (25.0) | 5 (13.5) | 160 (16.2) |
Missing/unknown | 23 (2.6) | 0 | 0 | 23 (2.3) |
Index biologic therapies, n (%) | ||||
Etanercept | 389 (44.2) | 31 (43.1) | 15 (40.5) | 435 (43.9) |
Adalimumab | 391 (44.4) | 32 (44.4) | 14 (37.8) | 437 (44.1) |
Infliximab | 67 (7.6) | 3 (4.2) | 7 (18.9) | 77 (7.8) |
Golimumab | 34 (3.9) | 6 (8.3) | 1 (2.7) | 41 (4.1) |
Comorbidities, n (%)c | ||||
Type 2 diabetes | 203 (23.0) | 11 (15.3) | 10 (27.0) | 224 (22.6) |
Hypertension | 400 (45.4) | 33 (45.8) | 18 (48.6) | 451 (45.6) |
Hyperlipidemia | 337 (38.3) | 23 (31.9) | 15 (40.5) | 375 (37.9) |
Ischemic heart disease | 75 (8.5) | 4 (5.6) | 4 (10.8) | 83 (8.4) |
Any of the above | 563 (63.9) | 41 (56.9) | 25 (67.6) | 629 (63.5) |